uric acid has been researched along with Hypertension, Essential in 37 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated changes in blood pressure (BP) and metabolic adverse effects, especially elevation of uric acid (UA), after treatment with a thiazide-like diuretic (TD) in patients with essential hypertension." | 9.34 | Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension. ( Hanada, H; Higaki, J; Higashiura, K; Horio, T; Hosomi, N; Igase, M; Ishimitsu, T; Iwashima, Y; Kamide, K; Katabuchi, R; Kato, J; Kawano, Y; Kojima, S; Komai, N; Matsuura, H; Miki, T; Miwa, Y; Miyata, T; Morimoto, S; Nakahama, H; Nakahashi, T; Nakamura, S; Ohta, Y; Oukura, T; Rakugi, H; Sasaguri, T; Sase, K; Shimamoto, K; Shinagawa, T; Soma, M; Sugimoto, K; Takeda, K; Takiuchi, S; Tomohiro Katsuya, T; Tsuchihashi, T; Ueno, M; Yoshihara, F, 2020) |
| "To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)." | 8.31 | Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023) |
| "Asymptomatic hyperuricemia (AHU) is elevated serum uric acid (UA) without symptoms." | 8.12 | Effects of uric acid-lowering therapy in patients with essential arterial hypertension. ( Bijak, M; Bilo, G; Drożdż, D; Drożdż, T; Gruszka, K; Hering, D; Jankowski, P; Rajzer, M; Terlecki, M; Wojciechowska, W, 2022) |
| "The prognostic value of serum uric acid (SUA) for incident acute coronary syndrome (ACS) in hypertensive subjects is uncertain." | 7.96 | J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Liu, L; Shen, G; Yu, YL; Zhang, B, 2020) |
| "To investigate the related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia." | 7.83 | Related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia. ( Lin, L; Wang, B; Zhao, C, 2016) |
| "Serum uric acid (UA) is independently associated with hypertension and blood pressure (BP) variability (BPV) is associated with cardiovascular events and mortality in hypertensive patients." | 7.81 | Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension. ( Çağlı, K; Canpolat, U; Covic, A; Kanbay, M; Mendi, MA; Öksüz, F; Özcan, F; Siriopol, D; Tok, D; Turak, O; Veisa, G, 2015) |
| " In the present study, blood triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) breakdown pathway was evaluated in relation to uric acid concentration and xanthine dehydrogenase/xanthine oxidase (XDH/XO) in patients with essential hypertension, patients with chronic renal diseases on dialysis, and control individuals." | 7.80 | Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. ( Boban, M; Bobana, MD; Cvetkovic, T; Deljanin-Ilic, M; Djindjic, B; Ilic, S; Jevtovic-Stoimenov, T; Kocic, G; Pavlovic, R; Radenkovic, S; Sokolovic, D; Stojanovic, D, 2014) |
| "We assessed whether red cell distribution width (RDW) is associated with serum uric acid (UA) level in a group of 512 patients with newly diagnosed hypertension, recruited in Beijing." | 7.80 | Relationship between red cell distribution width and serum uric acid in patients with untreated essential hypertension. ( Chen, LZ; Chen, P; Hu, YY; Li, YY; Li, ZZ; Luo, M; Yan, SP, 2014) |
| "Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg." | 6.79 | Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. ( Cheng, J; Hamada, T; Hirata, S; Hisatome, I; Igawa, O; Kato, M; Kuwabara, M; Miyazaki, S; Mizuta, E; Moriwaki, Y; Ninomiya, H; Nosaka, Y; Ogino, K; Ohtahara, A; Yamamoto, K; Yamamoto, Y; Yoshida, A, 2014) |
| "Uric acid (UA) is an independent prognostic factor for cardiovascular events, but there are no data demonstrating a different risk profile between women and men." | 5.91 | Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study. ( Andreozzi, F; Caroleo, B; Gigliotti, S; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Shehaj, E; Suraci, E, 2023) |
| "Insulin resistance was assessed by the homeostatic model assessment (HOMA) index." | 5.56 | Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance. ( Andreozzi, F; Armentaro, G; Cassano, V; Crescibene, D; Hribal, ML; Magurno, M; Maio, R; Miceli, S; Pelaia, C; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Toscani, A, 2020) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 5.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| "Hypertension was defined according to blood pressure readings by definitions of the Seventh Report of the Joint National Committee." | 5.40 | Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study. ( Jha, B; Kumar, A; Poudel, B; Raut, KB; Yadav, BK, 2014) |
| "We investigated changes in blood pressure (BP) and metabolic adverse effects, especially elevation of uric acid (UA), after treatment with a thiazide-like diuretic (TD) in patients with essential hypertension." | 5.34 | Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension. ( Hanada, H; Higaki, J; Higashiura, K; Horio, T; Hosomi, N; Igase, M; Ishimitsu, T; Iwashima, Y; Kamide, K; Katabuchi, R; Kato, J; Kawano, Y; Kojima, S; Komai, N; Matsuura, H; Miki, T; Miwa, Y; Miyata, T; Morimoto, S; Nakahama, H; Nakahashi, T; Nakamura, S; Ohta, Y; Oukura, T; Rakugi, H; Sasaguri, T; Sase, K; Shimamoto, K; Shinagawa, T; Soma, M; Sugimoto, K; Takeda, K; Takiuchi, S; Tomohiro Katsuya, T; Tsuchihashi, T; Ueno, M; Yoshihara, F, 2020) |
| "To study the development of microalbuminuria (MAU) in essential hypertension (EHT), we investigated the association of MAU with central blood pressure (CBP), direct renin concentration (DRC), plasma aldosterone (PA), and uric acid (UA)." | 4.31 | Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study. ( Chou, H; Li, J; Li, Y; Shi, L; Wei, M; Yang, N, 2023) |
| "Asymptomatic hyperuricemia (AHU) is elevated serum uric acid (UA) without symptoms." | 4.12 | Effects of uric acid-lowering therapy in patients with essential arterial hypertension. ( Bijak, M; Bilo, G; Drożdż, D; Drożdż, T; Gruszka, K; Hering, D; Jankowski, P; Rajzer, M; Terlecki, M; Wojciechowska, W, 2022) |
| " Uric acids disorders in particular hyperuricemia are significant problems in essential hypertensive patients and can cause substantial morbidity and mortality." | 4.02 | Evaluation of uric acid disorders and associated factors in essential hypertensive patients at Wolkite University specialized hospital, Southern Ethiopia. ( Haile, K; Timerga, A, 2021) |
| "The prognostic value of serum uric acid (SUA) for incident acute coronary syndrome (ACS) in hypertensive subjects is uncertain." | 3.96 | J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension. ( Chen, CL; Feng, YQ; Huang, JY; Huang, YQ; Liu, L; Shen, G; Yu, YL; Zhang, B, 2020) |
| "To evaluate the effect of hyperuricemia (HU) on subclinical changes of left ventricle (LV) function and structure in patients with hypertension (HT) using three-dimensional speckle-tracking echocardiography (3DSTE) and to explore the relationships between serum uric acid (SUA) levels and three-dimensional speckle tracking echocardiography (3DSTE) parameters in hypertensive and nonhypertensive patients with HU." | 3.85 | Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study. ( Chen, Y; Fang, X; Jiang, L; Pan, C; Shu, X; Sun, M; Wang, X; Zhang, Z, 2017) |
| "To investigate the related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia." | 3.83 | Related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia. ( Lin, L; Wang, B; Zhao, C, 2016) |
| "Serum uric acid (UA) is independently associated with hypertension and blood pressure (BP) variability (BPV) is associated with cardiovascular events and mortality in hypertensive patients." | 3.81 | Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension. ( Çağlı, K; Canpolat, U; Covic, A; Kanbay, M; Mendi, MA; Öksüz, F; Özcan, F; Siriopol, D; Tok, D; Turak, O; Veisa, G, 2015) |
| " In the present study, blood triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) breakdown pathway was evaluated in relation to uric acid concentration and xanthine dehydrogenase/xanthine oxidase (XDH/XO) in patients with essential hypertension, patients with chronic renal diseases on dialysis, and control individuals." | 3.80 | Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. ( Boban, M; Bobana, MD; Cvetkovic, T; Deljanin-Ilic, M; Djindjic, B; Ilic, S; Jevtovic-Stoimenov, T; Kocic, G; Pavlovic, R; Radenkovic, S; Sokolovic, D; Stojanovic, D, 2014) |
| "We assessed whether red cell distribution width (RDW) is associated with serum uric acid (UA) level in a group of 512 patients with newly diagnosed hypertension, recruited in Beijing." | 3.80 | Relationship between red cell distribution width and serum uric acid in patients with untreated essential hypertension. ( Chen, LZ; Chen, P; Hu, YY; Li, YY; Li, ZZ; Luo, M; Yan, SP, 2014) |
| "Azelnidipine was administered to 72 patients at a daily dose of 8 mg or 16 mg." | 2.79 | Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. ( Cheng, J; Hamada, T; Hirata, S; Hisatome, I; Igawa, O; Kato, M; Kuwabara, M; Miyazaki, S; Mizuta, E; Moriwaki, Y; Ninomiya, H; Nosaka, Y; Ogino, K; Ohtahara, A; Yamamoto, K; Yamamoto, Y; Yoshida, A, 2014) |
| "Uric acid (UA) is an independent prognostic factor for cardiovascular events, but there are no data demonstrating a different risk profile between women and men." | 1.91 | Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study. ( Andreozzi, F; Caroleo, B; Gigliotti, S; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Shehaj, E; Suraci, E, 2023) |
| "Insulin resistance was assessed by the homeostatic model assessment (HOMA) index." | 1.56 | Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance. ( Andreozzi, F; Armentaro, G; Cassano, V; Crescibene, D; Hribal, ML; Magurno, M; Maio, R; Miceli, S; Pelaia, C; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Toscani, A, 2020) |
| "Whether hyperuricemia is the cause or the effect is debatable." | 1.48 | Hypertension as Determinant of Hyperuricemia: A Case Control Study from the Sub-Himalayan Region in North India. ( Agarwal, VK; Kapoor, D; Raina, S; Sharma, KN; Yadav, RS, 2018) |
| "Hyperuricemia is associated with incident cardiovascular events in different settings of patients." | 1.46 | Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension. ( Addesi, D; Baggetta, R; Cimellaro, A; Maio, R; Perticone, F; Perticone, M; Sciacqua, A; Sesti, G; Tripepi, G, 2017) |
| "Uric acid is a powerful determinant of blood pressure over time, independent of lifestyle modifications." | 1.43 | Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk. ( Antolini, L; Genovesi, S; Giussani, M; Orlando, A; Pontremoli, R; Rebora, P; Stella, A; Valsecchi, MG; Viazzi, F, 2016) |
| "Hypertension was defined according to blood pressure readings by definitions of the Seventh Report of the Joint National Committee." | 1.40 | Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study. ( Jha, B; Kumar, A; Poudel, B; Raut, KB; Yadav, BK, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 21 (56.76) | 24.3611 |
| 2020's | 13 (35.14) | 2.80 |
| Authors | Studies |
|---|---|
| Timerga, A | 1 |
| Haile, K | 1 |
| Gruszka, K | 1 |
| Drożdż, T | 1 |
| Wojciechowska, W | 1 |
| Jankowski, P | 1 |
| Terlecki, M | 1 |
| Bijak, M | 1 |
| Hering, D | 1 |
| Bilo, G | 1 |
| Drożdż, D | 1 |
| Rajzer, M | 1 |
| Nugent, JT | 1 |
| Jiang, K | 1 |
| Funaro, MC | 1 |
| Saran, I | 1 |
| Young, C | 1 |
| Ghazi, L | 1 |
| Bakhoum, CY | 1 |
| Wilson, FP | 1 |
| Greenberg, JH | 1 |
| Li, J | 1 |
| Yang, N | 1 |
| Chou, H | 1 |
| Shi, L | 1 |
| Wei, M | 1 |
| Li, Y | 1 |
| Perticone, M | 3 |
| Maio, R | 3 |
| Shehaj, E | 1 |
| Gigliotti, S | 1 |
| Caroleo, B | 1 |
| Suraci, E | 1 |
| Sciacqua, A | 3 |
| Andreozzi, F | 2 |
| Perticone, F | 3 |
| Shen, G | 1 |
| Huang, JY | 1 |
| Yu, YL | 1 |
| Liu, L | 2 |
| Chen, CL | 1 |
| Zhang, B | 1 |
| Huang, YQ | 2 |
| Feng, YQ | 2 |
| Ohta, Y | 1 |
| Kamide, K | 2 |
| Hanada, H | 1 |
| Morimoto, S | 1 |
| Nakahashi, T | 1 |
| Takiuchi, S | 1 |
| Ishimitsu, T | 1 |
| Tsuchihashi, T | 1 |
| Soma, M | 1 |
| Tomohiro Katsuya, T | 1 |
| Sugimoto, K | 1 |
| Rakugi, H | 2 |
| Oukura, T | 1 |
| Higaki, J | 1 |
| Matsuura, H | 1 |
| Shinagawa, T | 1 |
| Miwa, Y | 1 |
| Sasaguri, T | 1 |
| Igase, M | 1 |
| Miki, T | 1 |
| Takeda, K | 1 |
| Higashiura, K | 1 |
| Shimamoto, K | 1 |
| Katabuchi, R | 1 |
| Ueno, M | 1 |
| Hosomi, N | 1 |
| Kato, J | 1 |
| Komai, N | 1 |
| Kojima, S | 3 |
| Sase, K | 1 |
| Iwashima, Y | 1 |
| Yoshihara, F | 1 |
| Horio, T | 1 |
| Nakamura, S | 1 |
| Nakahama, H | 1 |
| Miyata, T | 1 |
| Kawano, Y | 1 |
| Bhardwaj, R | 1 |
| Jain, R | 1 |
| Zhang, S | 1 |
| Lo, K | 1 |
| Tang, S | 1 |
| Leng, WX | 1 |
| Zhang, M | 1 |
| Cui, H | 1 |
| Zeng, LH | 1 |
| Hu, YX | 1 |
| Zhao, H | 1 |
| Zhang, Y | 1 |
| Liu, B | 1 |
| Zhang, L | 1 |
| Bao, M | 1 |
| Li, L | 1 |
| Zhao, N | 1 |
| Hussain, M | 1 |
| Wang, Y | 2 |
| Yi, J | 1 |
| Chen, P | 2 |
| Lu, C | 1 |
| Cassano, V | 1 |
| Crescibene, D | 1 |
| Hribal, ML | 1 |
| Pelaia, C | 1 |
| Armentaro, G | 1 |
| Magurno, M | 1 |
| Toscani, A | 1 |
| Miceli, S | 1 |
| Sesti, G | 2 |
| Mohd Nasir, MZ | 1 |
| Malek, KA | 1 |
| Isa, MR | 1 |
| Hamdan, MF | 1 |
| Abdul Kadir, RF | 1 |
| Ahmad, F | 1 |
| Wan Adib, WF | 1 |
| Tripepi, G | 1 |
| Cimellaro, A | 1 |
| Addesi, D | 1 |
| Baggetta, R | 1 |
| Georgiopoulos, G | 1 |
| Tsioufis, C | 2 |
| Kalos, T | 2 |
| Magkas, N | 1 |
| Roussos, D | 1 |
| Chrysohoou, C | 1 |
| Sarri, G | 1 |
| Syrmali, K | 1 |
| Georgakopoulos, P | 1 |
| Tousoulis, D | 2 |
| Andrikou, I | 1 |
| Dimitriadis, K | 1 |
| Konstantinidis, D | 1 |
| Kasiakogias, A | 1 |
| Kouremeti, M | 1 |
| Andrikou, E | 1 |
| Karapati, I | 1 |
| Fragoulis, C | 1 |
| Liatakis, I | 1 |
| Koutra, E | 1 |
| Kyriazopoulos, K | 1 |
| Thomopoulos, C | 1 |
| Ramirez, AJ | 1 |
| Christen, AI | 1 |
| Sanchez, RA | 1 |
| Lemiesz, M | 1 |
| Tenderenda-Banasiuk, E | 1 |
| Sosnowska, D | 1 |
| Taranta-Janusz, K | 1 |
| Wasilewska, A | 1 |
| Tayefi, M | 1 |
| Hassanian, SM | 1 |
| Maftouh, M | 1 |
| Moohebati, M | 1 |
| Bahrami, A | 1 |
| Parizadeh, SM | 1 |
| Mahdizadeh, A | 1 |
| Ghazizadeh, H | 1 |
| Bazeli, J | 1 |
| Heidari-Bakavoli, A | 1 |
| Kianifar, H | 1 |
| Mohammadzadeh, E | 1 |
| Rahmani, F | 1 |
| Esmaeili, H | 1 |
| Ebrahimi, M | 1 |
| Azarpazhooh, MR | 1 |
| Nematy, M | 1 |
| Safarian, M | 1 |
| Ferns, GA | 1 |
| Avan, A | 1 |
| Ghayour-Mobarhan, M | 1 |
| Raina, S | 1 |
| Agarwal, VK | 1 |
| Kapoor, D | 1 |
| Sharma, KN | 1 |
| Yadav, RS | 1 |
| Concistrè, A | 1 |
| Petramala, L | 1 |
| Bisogni, V | 1 |
| Mezzadri, M | 1 |
| Olmati, F | 1 |
| Saracino, V | 1 |
| Oliviero, G | 1 |
| Bonvicini, M | 1 |
| Tonnarini, G | 1 |
| Iannucci, G | 1 |
| Letizia, C | 1 |
| Poudel, B | 1 |
| Yadav, BK | 1 |
| Kumar, A | 1 |
| Jha, B | 1 |
| Raut, KB | 1 |
| Miyazaki, S | 1 |
| Hamada, T | 1 |
| Hirata, S | 1 |
| Ohtahara, A | 1 |
| Mizuta, E | 1 |
| Yamamoto, Y | 1 |
| Kuwabara, M | 1 |
| Nosaka, Y | 1 |
| Igawa, O | 1 |
| Ogino, K | 1 |
| Kato, M | 1 |
| Yoshida, A | 1 |
| Ninomiya, H | 1 |
| Cheng, J | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, K | 2 |
| Hisatome, I | 1 |
| Boban, M | 1 |
| Kocic, G | 1 |
| Radenkovic, S | 1 |
| Pavlovic, R | 1 |
| Cvetkovic, T | 1 |
| Deljanin-Ilic, M | 1 |
| Ilic, S | 1 |
| Bobana, MD | 1 |
| Djindjic, B | 1 |
| Stojanovic, D | 1 |
| Sokolovic, D | 1 |
| Jevtovic-Stoimenov, T | 1 |
| Luo, M | 1 |
| Li, ZZ | 1 |
| Li, YY | 1 |
| Chen, LZ | 1 |
| Yan, SP | 1 |
| Hu, YY | 1 |
| Çağlı, K | 1 |
| Turak, O | 1 |
| Canpolat, U | 1 |
| Özcan, F | 1 |
| Tok, D | 1 |
| Mendi, MA | 1 |
| Öksüz, F | 1 |
| Siriopol, D | 1 |
| Veisa, G | 1 |
| Covic, A | 1 |
| Kanbay, M | 1 |
| Giallauria, F | 1 |
| Predotti, P | 1 |
| Casciello, A | 1 |
| Grieco, A | 1 |
| Russo, A | 1 |
| Viggiano, A | 1 |
| Citro, R | 1 |
| Ravera, A | 1 |
| Ciardo, M | 1 |
| Guglielmi, M | 1 |
| Maggio, M | 1 |
| Vigorito, C | 1 |
| Viazzi, F | 1 |
| Rebora, P | 1 |
| Giussani, M | 1 |
| Orlando, A | 1 |
| Stella, A | 1 |
| Antolini, L | 1 |
| Valsecchi, MG | 1 |
| Pontremoli, R | 1 |
| Genovesi, S | 1 |
| Wang, B | 1 |
| Lin, L | 1 |
| Zhao, C | 1 |
| Schmitz, B | 1 |
| Brand, SM | 1 |
| Hifumi, A | 1 |
| Soejima, H | 1 |
| Ogawa, H | 1 |
| Fang, X | 1 |
| Pan, C | 1 |
| Chen, Y | 1 |
| Sun, M | 1 |
| Zhang, Z | 1 |
| Jiang, L | 1 |
| Wang, X | 1 |
| Shu, X | 1 |
| Hu, JW | 1 |
| Lv, YB | 1 |
| Chu, C | 1 |
| Wang, KK | 1 |
| Zheng, WL | 1 |
| Cao, YM | 1 |
| Yuan, ZY | 1 |
| Mu, JJ | 1 |
| STANTON, JR | 1 |
| FREIS, ED | 1 |
| Kawai, T | 1 |
| Ohishi, M | 1 |
| Takeya, Y | 1 |
| Onishi, M | 1 |
| Ito, N | 1 |
| MOSER, M | 1 |
| KRAWCZYNSKI, J | 1 |
| KUJAWA, J | 1 |
| TYBURCZYK, W | 1 |
| ZELAZOWSKA, M | 1 |
2 reviews available for uric acid and Hypertension, Essential
| Article | Year |
|---|---|
Does This Child With High Blood Pressure Have Secondary Hypertension?: The Rational Clinical Examination Systematic Review.
Topics: Adolescent; Blood Pressure Monitoring, Ambulatory; Child; Essential Hypertension; Humans; Hypertensi | 2023 |
The Role of Uric Acid in Hypertension of Adolescents, Prehypertension and Salt Sensitivity of Blood Pressure.
Topics: Adolescent; Age Factors; Blood Pressure; Essential Hypertension; Humans; Hypertension; Hyperuricemia | 2017 |
3 trials available for uric acid and Hypertension, Essential
| Article | Year |
|---|---|
Genetic factors associated with elevation of uric acid after treatment with thiazide-like diuretic in patients with essential hypertension.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Cross- | 2020 |
Effects of azelnidipine on uric acid metabolism in patients with essential hypertension.
Topics: Aged; Aged, 80 and over; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Creatin | 2014 |
Therapeutic strategy for efficient reduction of serum uric acid levels with allopurinol versus benzbromarone in hyperuricemic patients with essential hypertension - A randomized crossover study (terao study).
Topics: Aged; Aged, 80 and over; Allopurinol; Benzbromarone; Drug Administration Schedule; Drug Monitoring; | 2016 |
32 other studies available for uric acid and Hypertension, Essential
| Article | Year |
|---|---|
Evaluation of uric acid disorders and associated factors in essential hypertensive patients at Wolkite University specialized hospital, Southern Ethiopia.
Topics: Adult; Cross-Sectional Studies; Essential Hypertension; Ethiopia; Female; Health Knowledge, Attitude | 2021 |
Effects of uric acid-lowering therapy in patients with essential arterial hypertension.
Topics: Adult; Aged; Allopurinol; Blood Pressure; C-Reactive Protein; Carotid Intima-Media Thickness; Essent | 2022 |
Central diastolic blood pressure, plasma aldosterone and uric acid are associated with microalbuminuria in essential hypertension: a case-control study.
Topics: Albuminuria; Aldosterone; Blood Pressure; Case-Control Studies; Essential Hypertension; Humans; Hype | 2023 |
Sex-related differences for uric acid in the prediction of cardiovascular events in essential hypertension. A population prospective study.
Topics: Essential Hypertension; Female; Humans; Hypertension; Male; Prospective Studies; Risk Factors; Sex C | 2023 |
J-shaped association between serum uric acid and acute coronary syndrome in patients with essential hypertension.
Topics: Acute Coronary Syndrome; Aged; China; Essential Hypertension; Female; Humans; Hyperuricemia; Longitu | 2020 |
A Study of Serum Uric Acid Level in Essential Hypertension.
Topics: Essential Hypertension; Humans; Hypertension; Uric Acid | 2020 |
The association between serum uric acid levels and ischemic stroke in essential hypertension patients.
Topics: Biomarkers; Brain Ischemia; China; Essential Hypertension; Female; Humans; Kaplan-Meier Estimate; Ma | 2020 |
Correlations between indices of dynamic components of ambulatory blood pressure and renal damage in elderly Chinese male with essential hypertension.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2020 |
A pilot study to identify the longitudinal serum metabolite profiles to predict the development of hyperuricemia in essential hypertension.
Topics: Essential Hypertension; Humans; Hypertension; Hyperuricemia; Longitudinal Studies; Pilot Projects; U | 2020 |
Uric Acid and Vascular Damage in Essential Hypertension: Role of Insulin Resistance.
Topics: Adult; Atherosclerosis; Biomarkers; C-Reactive Protein; Essential Hypertension; Female; Humans; Insu | 2020 |
Association between elevated carotid intima-media thickness and serum uric acid levels among patients with essential hypertension in primary care setting in Sungai Buloh, Malaysia.
Topics: Carotid Arteries; Carotid Intima-Media Thickness; Cross-Sectional Studies; Essential Hypertension; H | 2021 |
Risk reclassification ability of uric acid for cardiovascular outcomes in essential hypertension.
Topics: Adult; Aged; Biomarkers; Cardiovascular Diseases; Cohort Studies; Essential Hypertension; Female; Fo | 2017 |
Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension.
Topics: Aged; Biomarkers; Diastole; Essential Hypertension; Female; Humans; Hyperuricemia; Male; Middle Aged | 2019 |
Uric acid as an independent predictor of coronary artery disease in essential hypertension: Data from an 8-year-follow-up study.
Topics: Biomarkers; Coronary Artery Disease; Essential Hypertension; Female; Humans; Incidence; Kaplan-Meier | 2018 |
Serum Uric Acid Elevation is Associated to Arterial Stiffness in Hypertensive Patients with Metabolic Disturbances.
Topics: Arterial Pressure; Biomarkers; Blood Glucose; Cross-Sectional Studies; Essential Hypertension; Femal | 2018 |
Serum Renalase Levels in Adolescents with Primary Hypertension.
Topics: Adolescent; Biomarkers; Blood Pressure; Blood Pressure Determination; Child; Cohort Studies; Essenti | 2018 |
Relationship between platelet count and platelet width distribution and serum uric acid concentrations in patients with untreated essential hypertension.
Topics: Adult; Anthropometry; Biomarkers; Blood Platelets; Blood Pressure; C-Reactive Protein; Cholesterol, | 2018 |
Hypertension as Determinant of Hyperuricemia: A Case Control Study from the Sub-Himalayan Region in North India.
Topics: Case-Control Studies; Essential Hypertension; Female; Humans; Hyperuricemia; India; Male; Sex Factor | 2018 |
Subclinical atherosclerosis due to increase of plasma aldosterone concentrations in essential hypertensive individuals.
Topics: Adult; Aldosterone; Ankle Brachial Index; Atherosclerosis; Biomarkers; Carotid Intima-Media Thicknes | 2019 |
Serum uric acid level in newly diagnosed essential hypertension in a Nepalese population: a hospital based cross sectional study.
Topics: Adult; Aged; Cross-Sectional Studies; Essential Hypertension; Female; Humans; Hypertension; Hyperuri | 2014 |
Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease.
Topics: Adenine Nucleotides; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Blood P | 2014 |
Relationship between red cell distribution width and serum uric acid in patients with untreated essential hypertension.
Topics: Cross-Sectional Studies; Erythrocyte Count; Erythrocytes; Essential Hypertension; Female; Humans; Hy | 2014 |
Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension.
Topics: Aged; Blood Pressure; Blood Pressure Determination; Blood Pressure Monitoring, Ambulatory; Circadian | 2015 |
Serum uric acid is associated with non-dipping circadian pattern in young patients (30-40 years old) with newly diagnosed essential hypertension.
Topics: Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Circadian Rhythm; | 2016 |
Increased Serum Uric Acid Levels Blunt the Antihypertensive Efficacy of Lifestyle Modifications in Children at Cardiovascular Risk.
Topics: Anthropometry; Antihypertensive Agents; Biomarkers; Blood Pressure; Blood Pressure Determination; Bo | 2016 |
Related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia.
Topics: Adult; Aged; Blood Glucose; China; Cholesterol; Creatinine; Cross-Sectional Studies; Essential Hyper | 2016 |
Uric acid and essential hypertension: the endothelial connection.
Topics: Essential Hypertension; Humans; Hypertension; Hyperuricemia; Uric Acid | 2016 |
Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study.
Topics: Aged; Echocardiography; Echocardiography, Three-Dimensional; Essential Hypertension; Female; Heart V | 2017 |
The serum uric acid concentration in essential hypertension.
Topics: Essential Hypertension; Humans; Hypertension; Uric Acid | 1947 |
Serum uric acid is an independent risk factor for cardiovascular disease and mortality in hypertensive patients.
Topics: Biomarkers; Cardiovascular Diseases; Cohort Studies; Essential Hypertension; Female; Follow-Up Studi | 2012 |
COMBINATION DRUG THERAPY OF ESSENTIAL HYPERTENSION.
Topics: Antihypertensive Agents; Blood; Blood Pressure; Blood Pressure Determination; Diuretics; Drug Therap | 1964 |
Diurnal variations in renal excretion of electrolytes, uric acid and total amino nitrogen in various renal diseases and in essential hypertension.
Topics: Electrolytes; Essential Hypertension; Humans; Hypertension; Kidney Diseases; Nitrogen; Periodicity; | 1961 |